English 中文简体 中文繁体

KN046 Research Findings to be Presented at CSCO 2019

September 11, 2019 16:00 Eastern Daylight Time

SUZHOU, China, September XX, 2019 — Alphamab Oncology announced that two clinical study abstracts of KN046, an innovative PD-L1/CTLA-4 bispecific antibody, were received by the Annual Meeting of Chinese Society of Clinical Oncology (CSCO) 2019 recently. The latest study data will be presented both as verbal presentation and as a poster presentation.


The CSCO Annual Meeting is a domestic academic conference in the field of clinical oncology with the largest scale and highest level in China. The CSCO 2019, with the theme of “Precision & Intelligence: Hope to conquer cancer”, is expected to attract attendance of  tens of thousands of domestic and international speakers, oncologists, research scholars, and pharmaceutical practitioners to provide a great opportunity for global communication and cooperation on clinical oncology.


The CSCO Annual Meeting Innovation Session is dedicated for exchange of clinical trial data. From September 19th to 21st, two breakthrough clinical study results of KN046 will be presented in the Innovation Session.


A report of "Preliminary study summary of the safety, tolerability, pharmacokinetics and antitumor activity of KN046 in patients with advanced solid tumors in China” will be verbally presented by Professor Li Zhang from Center of Cancer Prevention and Treatment of Sun Yat-sen University. (Reporting Session: Innovative Drug Clinical Study Data Session 2 in the afternoon of September 21st).


In addition, "Selecting the recommended dose for phase 2 clinical study based on the KN046 PK/PD model and the preliminary exposure-response relationship" will be presented as a poster (Board No.: C-4, Innovation Session Poster Zone, 2nd floor of Xiamen International Conference Center).


KN046 is the world's first recombinant humanized PD-L1/CTLA-4 bispecific antibody independently developed by Alphamab Oncology. Its innovative designs include:

 a bispecific antibody fused with PD-L1 antibody;

engineered to target the tumor microenvironment with high PD-L1 expression;

a proprietary CTLA-4 domain antibody with significantly improved safety;

Treg clearing function


The preclinical and clinical study results of KN046 have shown a promising efficacy and toxicity to human peripheral system, with the potential to become the cornerstone of next generation immuno-oncology therapy in the future.


KN046-CHN-001 is a clinical study on the safety, tolerability, pharmacokinetic, and antitumor activity in advanced solid tumor patients in China. According to the study, the recommended dose for phase II is tentatively determined and potential therapeutic signals are observed.


Previously, KN046's phase I clinical trials in Australia and China have shown preliminarily good safety and promising efficacy, and several phase II clinical trials have been initiated in China for NSCLC, TNBC and ESCC.